EE05385B1 - LaiaspektrilisedÁ2-(asendatudÁamino)bensotiasoolsulfoonamiididÁkuiÁHIVÁproteaasiÁinhibiitorid,ÁnendeÁvalmistamismeetodÁjaÁkasutamineÁningÁfarmatseutilineÁkompositsioon - Google Patents

LaiaspektrilisedÁ2-(asendatudÁamino)bensotiasoolsulfoonamiididÁkuiÁHIVÁproteaasiÁinhibiitorid,ÁnendeÁvalmistamismeetodÁjaÁkasutamineÁningÁfarmatseutilineÁkompositsioon

Info

Publication number
EE05385B1
EE05385B1 EEP200300381A EEP200300381A EE05385B1 EE 05385 B1 EE05385 B1 EE 05385B1 EE P200300381 A EEP200300381 A EE P200300381A EE P200300381 A EEP200300381 A EE P200300381A EE 05385 B1 EE05385 B1 EE 05385B1
Authority
EE
Estonia
Prior art keywords
ákuiáhiváprotease
áamino
useunited
sulphonamides
benzothiazole
Prior art date
Application number
EEP200300381A
Other languages
English (en)
Estonian (et)
Inventor
Dominique�Louis�Nestor�Ghislain�Surleraux
Piet�Tom�Bert�Paul�Wigerinck
Daniel�Getman
Wim�Gaston�Verschueren
Sandrine�Marie�Helene�Vendeville
Marie-Pierre�T.M.M.G�De�Bethune
Jan�Octaaf�Antoon�De�Kerpel
Samuel�Leo�Christiaan�Moors
Herman�Augustinus�De�Kock
Marieke�Christiane�Johanna�Voets
Original Assignee
Tibotec�Pharmaceuticals�Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tibotec�Pharmaceuticals�Ltd. filed Critical Tibotec�Pharmaceuticals�Ltd.
Publication of EE200300381A publication Critical patent/EE200300381A/xx
Publication of EE05385B1 publication Critical patent/EE05385B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
EEP200300381A 2001-02-14 2002-02-14 LaiaspektrilisedÁ2-(asendatudÁamino)bensotiasoolsulfoonamiididÁkuiÁHIVÁproteaasiÁinhibiitorid,ÁnendeÁvalmistamismeetodÁjaÁkasutamineÁningÁfarmatseutilineÁkompositsioon EE05385B1 (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01200529 2001-02-14
US28775801P 2001-05-02 2001-05-02
PCT/EP2002/001788 WO2002083657A2 (fr) 2001-02-14 2002-02-14 Sulfamides de 2-amino-benzothiazole substitue en tant qu'inhibiteurs de la protease du vih a large spectre

Publications (2)

Publication Number Publication Date
EE200300381A EE200300381A (et) 2003-12-15
EE05385B1 true EE05385B1 (et) 2011-02-15

Family

ID=26076833

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200300381A EE05385B1 (et) 2001-02-14 2002-02-14 LaiaspektrilisedÁ2-(asendatudÁamino)bensotiasoolsulfoonamiididÁkuiÁHIVÁproteaasiÁinhibiitorid,ÁnendeÁvalmistamismeetodÁjaÁkasutamineÁningÁfarmatseutilineÁkompositsioon

Country Status (31)

Country Link
US (1) US7659404B2 (fr)
EP (1) EP1370543B1 (fr)
JP (1) JP4530612B2 (fr)
KR (1) KR100870184B1 (fr)
CN (2) CN101230067B (fr)
AP (1) AP1504A (fr)
AT (1) ATE343567T1 (fr)
AU (1) AU2002302363B2 (fr)
BG (1) BG66301B1 (fr)
BR (1) BR0207862A (fr)
CA (1) CA2438304C (fr)
CY (1) CY1108073T1 (fr)
CZ (1) CZ304273B6 (fr)
DE (1) DE60215623T2 (fr)
DK (1) DK1370543T3 (fr)
EA (1) EA006096B1 (fr)
EE (1) EE05385B1 (fr)
ES (1) ES2275866T3 (fr)
HK (1) HK1061233A1 (fr)
HR (1) HRP20030735B1 (fr)
HU (1) HU229224B1 (fr)
IL (2) IL157171A0 (fr)
MX (1) MXPA03007236A (fr)
NO (1) NO326174B1 (fr)
NZ (1) NZ527391A (fr)
PL (1) PL213327B1 (fr)
PT (1) PT1370543E (fr)
SI (1) SI1370543T1 (fr)
SK (1) SK287582B6 (fr)
WO (1) WO2002083657A2 (fr)
ZA (1) ZA200306086B (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ516259A (en) 1999-05-28 2004-02-27 Virco N New mutational profiles in HIV-1 reverse transcriptase correlated with phenotypic drug resistance
AU2002226316B2 (en) 2000-10-20 2008-06-26 Virco Bvba Mutational profiles in HIV-1 reverse transcriptase correlated with phenotypic drug resistance
HU229224B1 (en) 2001-02-14 2013-09-30 Tibotec Pharmaceuticals Ltd Little Island 2-(substituted-amino)-benzothiazole sulfonamide compounds having broadspectrum hiv protease inhibitor activity and medicaments containing them
US20040009890A1 (en) 2002-01-07 2004-01-15 Erickson John W. Broad spectrum inhibitors
US7157489B2 (en) 2002-03-12 2007-01-02 The Board Of Trustees Of The University Of Illinois HIV protease inhibitors
EP1522039B1 (fr) 2002-07-01 2008-06-04 Tibotec Pharmaceuticals Ltd. Nouveaux profils mutationnels dans une transcriptase inverse du vih-1 correles a une resistance phenotypique aux medicaments
AU2003254500B2 (en) 2002-07-01 2009-11-19 Tibotec Pharmaceuticals Ltd. Mutational profiles in HIV-1 protease correlated with phenotypic drug resistance
CN101445493A (zh) * 2002-08-02 2009-06-03 泰博特克药品有限公司 广谱2-氨基-苯并噻唑磺酰胺类hiv蛋白酶抑制剂
NZ538488A (en) * 2002-08-02 2007-10-26 Tibotec Pharm Ltd Broadspectrum 2-amino-benzothiazole sulfonamide HIV protease inhibitors
KR101090102B1 (ko) * 2003-09-30 2011-12-07 티보텍 파마슈티컬즈 벤조옥사졸 설폰아미드 화합물 및 그의 중간체를 제조하는방법
DE10360835A1 (de) * 2003-12-23 2005-07-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclische Imidazolverbindungen, deren Herstellung und deren Verwendung als Arzneimittel
EP1750696B1 (fr) * 2004-05-07 2013-06-26 Sequoia Pharmaceuticals Inc Inhibiteurs de protéase rétrovirale repoussant leur résistance
RU2421459C2 (ru) 2005-02-25 2011-06-20 Тиботек Фармасьютикалз Лтд. Синтез предшественника ингибитора протеазы
AR053845A1 (es) 2005-04-15 2007-05-23 Tibotec Pharm Ltd 5-tiazolilmetil[(1s,2r)-3-[[(2-amino-6-benzoxazolil)sulfonil)](2-metilpropil)amino]-2-hidroxi-1-(fenilmetil)propil]carbamato como mejorador de farmacos metabolizados por el citocromo p450
JO2841B1 (en) 2006-06-23 2014-09-15 تيبوتيك فارماسيوتيكالز ليمتد 2-(substituted-amino) -benzothiazole sulfonamide as protease inhibitors HIV (HIV)
WO2011061590A1 (fr) 2009-11-17 2011-05-26 Hetero Research Foundation Nouveaux dérivés carboxamides comme inhibiteurs du vih
JO3090B1 (ar) * 2009-12-11 2017-03-15 Janssen Sciences Ireland Uc 5- امينو-4- هيدروكسي-بنتويل اميدات
US9024038B2 (en) * 2010-12-27 2015-05-05 Purdue Research Foundation Compunds and methods for treating HIV
PE20141558A1 (es) 2012-04-20 2014-11-06 Gilead Sciences Inc Derivados de acido benzotiazol-6-il acetico y su uso para tratar una infeccion por vih
CN104000824B (zh) * 2014-05-28 2016-07-06 中山大学 苯并五元杂环类化合物在制备抗hiv-1病毒药物中的应用
US11439608B2 (en) 2017-09-25 2022-09-13 Qun Lu Roles of modulators of intersectin-CDC42 signaling in Alzheimer's disease

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2093073T3 (es) 1990-03-09 1996-12-16 Milliken Res Corp Materiales organicos que tienen restos poli(oxialquilenos) enlazados por un grupo sulfonamido y su preparacion.
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
ATE172717T1 (de) 1992-08-25 1998-11-15 Searle & Co Hydroxyethylaminosulfonamide verwendbar als inhibitoren retroviraler proteasen
PH30929A (en) 1992-09-03 1997-12-23 Janssen Pharmaceutica Nv Beads having a core coated with an antifungal and a polymer.
IS2334B (is) * 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
EP0715618B1 (fr) 1993-08-24 1998-12-16 G.D. Searle & Co. Hydroxyethylamino-sulfonamides aptes a etre utilises comme inhibiteurs de protease retrovirale
HU222355B1 (hu) 1993-10-01 2003-06-28 Astra Aktiebolag Eljárás és berendezés finom gyógyszerhatóanyag-porok kezelésére és feldolgozására
CA2210889C (fr) 1995-01-20 2007-08-28 G.D. Searle & Co. Inhibiteurs hydroxyethylamino contenant des bis-sulfinamides utilises pour inhiber des proteases retrovirales
US5756533A (en) 1995-03-10 1998-05-26 G.D. Searle & Co. Amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
US6140505A (en) 1995-03-10 2000-10-31 G. D. Searle & Co. Synthesis of benzo fused heterocyclic sulfonyl chlorides
US6143788A (en) * 1995-03-10 2000-11-07 G.D. Searle & Co. Bis-amino acid hydroxyethlamino sulfonamide retroviral protease inhibitors
US6861539B1 (en) * 1995-03-10 2005-03-01 G. D. Searle & Co. Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
US6150556A (en) * 1995-03-10 2000-11-21 G. D. Dearle & Co. Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
US5705500A (en) * 1995-03-10 1998-01-06 G.D. Searle & Co. Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors
AU717598B2 (en) * 1995-03-10 2000-03-30 G.D. Searle & Co. Heterocyclecarbonyl amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
JP2000515488A (ja) * 1995-11-15 2000-11-21 ジー．ディー．サール アンド カンパニー 置換スルホニルアルカノイルアミノヒドロキシエチルアミノスルホンアミド レトロウイルスプロテアーゼ阻害剤
TR199801225T2 (xx) 1996-05-20 1998-11-23 Janssen Pharmaceutica N.V. Geli�tirilmi� biyolojik kullan�l�rl��a sahip antifungal bile�imler.
RU2218153C2 (ru) 1997-03-26 2003-12-10 Жансен Фармасетика Н.В. Драже, имеющее ядро, покрытое противогрибковым средством и полимером
HUP0101598A3 (en) 1997-12-24 2002-08-28 Vertex Pharmaceuticals Inc Cam Prodrugs of aspartyl protease inhibitors and medicaments containing them
WO1999033792A2 (fr) 1997-12-24 1999-07-08 Vertex Pharmaceuticals Incorporated Promedicaments des inhibiteurs de l'aspartyl-transferase
AU2012199A (en) 1997-12-24 1999-07-19 Vertex Pharmaceuticals Incorporated Prodrugs of aspartyl protease inhibitors
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
PT1086076E (pt) * 1998-06-19 2005-05-31 Vertex Pharma Inibidores de sulfonamida de aspartil protease
WO1999067254A2 (fr) 1998-06-23 1999-12-29 The United States Of America Represented By The Secretary, Department Of Health And Human Services Inhibiteurs de protease retrovirale resistant a l'action de plusieurs medicaments et procedes associes
EP2336134B1 (fr) * 1998-06-23 2016-08-31 The United States of America, represented by the Secretary, Department of Health and Human Services Analyse de potentiel biochimique et méthodes pour réduire la résistance de VIH dans la thérapie
AR031520A1 (es) 1999-06-11 2003-09-24 Vertex Pharma Un compuesto inhibidor de aspartilo proteasa, una composicion que lo comprende y un metodo para tratar un paciente con dicha composicion
HU229224B1 (en) 2001-02-14 2013-09-30 Tibotec Pharmaceuticals Ltd Little Island 2-(substituted-amino)-benzothiazole sulfonamide compounds having broadspectrum hiv protease inhibitor activity and medicaments containing them

Also Published As

Publication number Publication date
PT1370543E (pt) 2007-02-28
ZA200306086B (en) 2005-01-26
BG108143A (en) 2004-07-30
KR100870184B1 (ko) 2008-11-24
HRP20030735A2 (en) 2005-08-31
SK11022003A3 (sk) 2004-07-07
NO20033584L (no) 2003-10-14
CN100369904C (zh) 2008-02-20
AP2003002856A0 (en) 2003-09-30
HU229224B1 (en) 2013-09-30
JP2004518767A (ja) 2004-06-24
PL213327B1 (pl) 2013-02-28
EA006096B1 (ru) 2005-08-25
CZ304273B6 (cs) 2014-02-12
HK1061233A1 (en) 2004-09-10
CZ20032415A3 (cs) 2004-04-14
NO326174B1 (no) 2008-10-13
WO2002083657A2 (fr) 2002-10-24
JP4530612B2 (ja) 2010-08-25
CY1108073T1 (el) 2014-02-12
AP1504A (en) 2005-12-10
CN101230067A (zh) 2008-07-30
EP1370543A2 (fr) 2003-12-17
MXPA03007236A (es) 2003-12-04
BR0207862A (pt) 2004-06-22
EP1370543B1 (fr) 2006-10-25
DK1370543T3 (da) 2007-02-19
AU2002302363B2 (en) 2008-05-01
SK287582B6 (sk) 2011-03-04
DE60215623D1 (de) 2006-12-07
CA2438304C (fr) 2011-04-12
ES2275866T3 (es) 2007-06-16
CN101230067B (zh) 2011-06-15
KR20030077017A (ko) 2003-09-29
NZ527391A (en) 2005-04-29
EE200300381A (et) 2003-12-15
HRP20030735B1 (en) 2012-02-29
US20040116485A1 (en) 2004-06-17
CN1525962A (zh) 2004-09-01
EA200300891A1 (ru) 2004-02-26
BG66301B1 (bg) 2013-03-29
ATE343567T1 (de) 2006-11-15
DE60215623T2 (de) 2007-08-30
IL157171A (en) 2012-10-31
WO2002083657A3 (fr) 2003-02-13
CA2438304A1 (fr) 2002-10-24
SI1370543T1 (sl) 2007-04-30
HUP0303257A2 (hu) 2004-01-28
IL157171A0 (en) 2004-02-08
PL363778A1 (en) 2004-11-29
US7659404B2 (en) 2010-02-09
NO20033584D0 (no) 2003-08-13

Similar Documents

Publication Publication Date Title
EE05385B1 (et) LaiaspektrilisedÁ2-(asendatudÁamino)bensotiasoolsulfoonamiididÁkuiÁHIVÁproteaasiÁinhibiitorid,ÁnendeÁvalmistamismeetodÁjaÁkasutamineÁningÁfarmatseutilineÁkompositsioon
NO20033556D0 (no) Farmasöytiske preparater
DK1478339T3 (da) Farmaceutiske formuleringer af antineoplastiske midler, specielt temozolomid, fremgangsmåder til fremstilling og anvendelse heraf
IS7714A (is) Lyfjasamsetningar úr módafíníl
AU2002363236A1 (en) Compounds, pharmaceutical compositions and methods of use therefor
NO20033384D0 (no) Farmasöytisk formulering
NO20040356L (no) Indaneddiksyrederivater og deres andvendelse som farmasoytiske midler, intermediater og fremgangsmate for fremstilling.
IS6934A (is) Nýjar spírótrísýklískar afleiður og notkun þeirrasem fosfódíesterasa-7-hindrar
NO20033785L (no) Farmasöytisk formulering
NO20044192L (no) 17alfa-alkyl-17beta-oksy-ostratriener og farmasoytiske preparater
NO20024528L (no) Proteaseinhibitor, farmasoytisk sammensetning og anvendelse av forbindelsen
NO20041272L (no) Tetracycline derivatives and methods of use thereof
NO20040268L (no) Nye 2H-pyridazin-3-derivater, farmasoytiske preparater inneholdende slike og fremgangsmate for fremstilling av den aktive ingrediensen
IS2707B (is) Nýjar lyfjasamsetningar úr módafíníli
NO20044916L (no) Preparater av sulfinylacetamid
IS7798A (is) Efnasambönd, lyfjablöndur og aðferðir
NO20035627D0 (no) Farmasöytisk formulering
NO20033854L (no) N-but-3-enyl-norbuprenorfin og fremgangsmåter for anvendelse
NO20035328D0 (no) Nye forbindelser og preparater som katepsinhibitorer
NO20033506L (no) Parasitticidale preparater og metoder for anvendelse
IS6956A (is) Sítrat salt af 5,8,14,-tríasatetrasýkló[10.3.1.02,11.04,9]-hexadeka-2(11),3,5,7,9-pentaen og lyfjafræðilegar samsetningar af því
DK1387838T3 (da) Cyanoanthranylamid-derivater og deres anvendelse som lægemidler
EE200300501A (et) Ninna manustatavad imidasotriasinooni sisaldavad kompositsioonid
EE05384B1 (et) LaiaspektrilisedÁ2-(asendatudÁamino)bensoksasoolsulfoonamiididÁkuiÁHIVÁproteaasiÁinhibiitorid,ÁnendeÁkasutamine,ÁfarmatseutilineÁkompositsioonÁjaÁmeetodÁretroviiruseÁreplikatsiooniÁinhibeerimiseks
DK1407780T3 (da) Farmaceutisk stabile hæmostatiske præparater

Legal Events

Date Code Title Description
HE1A Change of address
HE1A Change of address
MM4A Lapsed by not paying the annual fees

Effective date: 20160214